Special Issue "Personalized Medicine in Rheumatology—towards Adapting Our Care to Manifold Patient Phenotypes"
Deadline for manuscript submissions: closed (25 October 2023) | Viewed by 4733
2. Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet, 171 76 Stockholm, Sweden
Interests: outcomes research; clinical and observational trials; digital health; collaborative research; autoantibodies; inflammatory arthritis
2. Department of Rheumatology, Silkeborg Regional Hospital, Silkeborg, Denmark
Interests: translational research; basic science; drug discovery; biomarkers; pharmacology; development of treatment recommendations; inflammatory arthritis
Rheumatologic and musculoskeletal diseases are a worldwide burden in terms of quality of life and socioeconomics, with effects reaching beyond those affected directly to also impact society at large. During the past several decades, treatment advances have improved the therapeutic options for many rheumatic conditions. Inflammatory arthritis and rheumatoid arthritis represent the most prevalent of these conditions, and people affected with these conditions have benefitted greatly from modern therapeutic options. Despite the tremendous increase in the treatment armamentarium and better and harmonized definitions of outcomes, in order to facilitate comparability between trials, a significant proportion of patients struggle with the condition and common associated comorbidities. The ideal treatment option for an individual patient remains as only one of the most urgent puzzles to solve, in order to be able to assist patients in abating disease activity as soon as possible. At this point, research is needed on all areas related to this topic, starting from the prevention of disease or pre-disease stages as well as the prevention of difficult-to-treat cases.
The proposed Special Issue aims to collect the most recent insights into clinical and translational research, as well as works describing the implementation of novel methodological approaches for advances in personalized medicine. It may address unmet needs in rare rheumatologic autoimmune diseases, connective tissue diseases and the full spectrum of arthritic disorders to help in the further guidance of tailored patient care.
No specific restriction on the heterogeneity of rheumatic conditions applies. We are especially interested in the management of care, specific targeted therapies, treatment selection, patient stratification, the application of artificial intelligence to manage the increasing data influx in various patients as well as disease characteristics and associated -omics profiling.
We invite the submission of quantitative as well as qualitative clinical research or translational research of original work in the above outlined arena. Reviews or systematic literature reviews summarizing the complexity of this arena are also welcome.
Dr. Paul Studenic
Dr. Tue Wenzel Kragstrup
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- treatment choice
- artificial intelligence
- patient-centered care
- drug monitoring
- patient preference